NVS - Novartis Q3: Earnings Beat Raised Operating Profit Outlook & More | Benzinga
Novartis AG (NYSE: NVS) reported Q3 FY23 sales of $11.78 billion, up 12% Y/Y in reported and constant currency (cc), beating the consensus of $11.40 billion.
Sales growth was mainly driven by a continued strong performance from Entresto, Kesimpta, Pluvicto, Kisqali and Scemblix.
Heart failure drug Entresto sales are up 31% Y/Y in cc at $1.49 billion in the quarter.
Kesimpta, a new once-a-month injection against multiple sclerosis, quarterly revenues rocketed 124% Y/Y in cc to $657 million.
Sales of the newly launched Pluvicto, a radiotherapy against prostate cancer, were up 217% Y/Y in cc to $256 million on a now unconstrained supply chain and focus on new patients.
"Our robust pipeline also continues to deliver, and we have achieved important innovation ...